BeiGene Stock Price, News & Analysis (NASDAQ:BGNE)

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

12 brokerages have issued 12-month target prices for BeiGene's stock. Their BGNE share price targets range from $196.00 to $350.00. On average, they expect the company's stock price to reach $278.08 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $219.94 on January 1st, 2023. Since then, BGNE shares have decreased by 16.0% and is now trading at $184.84.
View the best growth stocks for 2023 here.

BeiGene saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,480,000 shares, an increase of 23.3% from the October 31st total of 1,200,000 shares. Based on an average daily volume of 213,200 shares, the days-to-cover ratio is currently 6.9 days.
View BeiGene's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our BGNE earnings forecast.

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Thursday, November, 9th. The company reported $2.01 EPS for the quarter, beating the consensus estimate of ($3.38) by $5.39. The company earned $781.30 million during the quarter, compared to the consensus estimate of $596.75 million. BeiGene had a negative net margin of 43.53% and a negative trailing twelve-month return on equity of 23.83%. The business's revenue was up 101.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($5.39) EPS.

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), VanEck Biotech ETF (BBH), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Biotechnology ETF (IBBQ).

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

BeiGene's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (5.16%), Baillie Gifford & Co. (3.99%), FMR LLC (2.43%), Invesco Ltd. (1.53%), Morgan Stanley (0.15%) and Mitsubishi UFJ Trust & Banking Corp (0.11%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Bros Advisors Lp Baker, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.